Predicting recurrence in intermediate‑ and high‑risk stage IB‑IIB cervical cancer treated with adjuvant cisplatin and paclitaxel chemotherapy post‑radical hysterectomy: The role of TBX2 expression

• Published in: Oncology letters Vol. 28; no. 3; p. 414
• Main Authors: Noda, Takuya, Fukuda, Takeshi, Uchikura, Eijiro, Awazu, Yuichiro, Wada, Takuma, Tasaka, Reiko, Yamauchi, Makoto, Yasui, Tomoyo, Sumi, Toshiyuki
• Format: Journal Article
• Language: English
• Published: Greece Spandidos Publications 01.09.2024; Spandidos Publications UK Ltd; D.A. Spandidos
• Subjects: Adjuvant treatment; Antimitotic agents; Antineoplastic agents; Cancer; Cancer therapies; Cell cycle; Cervical cancer; Chemotherapy; Development and progression; Embryonic development; Health aspects; Hysterectomy; Magnetic resonance imaging; Medical colleges; Oncology; Prognosis; Risk factors; RNA; Scientific equipment and supplies industry; Surgery; Women; World health; United States; Japan; adjuvant chemotherapy; paclitaxel; apoptosis; T-box 2; cisplatin; uterine cervical cancer
• ISSN: 1792-1074; 1792-1082
• DOI: 10.3892/ol.2024.14547

Cervical cancer remains a significant global health concern despite advances in prevention and treatment. Current management for intermediate- to high-risk stage IB-IIB cervical cancer post-radical hysterectomy involves irradiation or concurrent chemoradiation, although patients can exhibit several adverse events. Adjuvant chemotherapy has emerged as a promising alternative; however, its efficacy remains unclear. T-box (TBX)2 is a transcription factor that is involved in the regulation of cell cycle progression during cancer and embryonic development. Additionally, elevated expression of TBX2 is associated with resistance to DNA-damaging chemotherapeutic agents, such as cisplatin, carboplatin and doxorubicin. The aim of the present study was to investigate the relationship between TBX2 expression and recurrence in patients receiving adjuvant cisplatin and paclitaxel (TP) chemotherapy post-radical hysterectomy. Additionally, the impact of TBX2 knockdown on cisplatin sensitivity was assessed . A retrospective analysis was performed on 100 patients. Patients were categorized into two groups based on recurrence within 2 years of treatment initiation: The non-recurrent group (n=85) and the recurrent group (n=15). TBX2 expression was assessed immunohistochemically, and multiple logistic regression analysis was performed to identify predictors of recurrence. Additionally, the impact of small interfering RNA-mediated TBX2 knockdown on cervical cancer cell sensitivity to cisplatin was evaluated. TBX2 expression was significantly higher in the recurrent group compared with that in the non-recurrent group (P<0.01). Patients were stratified into low TBX2 expression (weighted score ≤8; n=80) and high TBX2 expression (weighted score ≥9; n=20) groups. The high TBX2 expression group exhibited a higher recurrence rate compared with the low expression group (P<0.01). Multivariate analysis identified TBX2 expression as an independent predictor of recurrence (P<0.01). Moreover, TBX2 knockdown significantly enhanced cervical cancer cell sensitivity to cisplatin (P<0.05). These findings highlight TBX2 expression as a potential predictive biomarker for recurrence amongst patients with intermediate- to high-risk stage IB-IIB cervical cancer receiving adjuvant TP chemotherapy post-radical hysterectomy.